The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates

Blood Rev. 2014 Nov;28(6):235-41. doi: 10.1016/j.blre.2014.07.005. Epub 2014 Aug 24.

Abstract

Since 1990, several techniques have been developed to photochemically inactivate pathogens in platelet concentrates, potentially leading to safer transfusion therapy. The three most common methods are amotosalen/UVA (INTERCEPT Blood System), riboflavin/UVA-UVB (MIRASOL PRT), and UVC (Theraflex-UV). We review the biology of pathogen inactivation methods, present their efficacy in reducing pathogens, discuss their impact on the functional aspects of treated platelets, and review clinical studies showing the clinical efficiency of the pathogen inactivation methods and their possible toxicity.

Keywords: Amotosalen; Hemovigilance; Pathogen inactivation; Pathogen reduction; Platelet concentrates; Platelets; Riboflavin; Transfusion.

Publication types

  • Review

MeSH terms

  • Blood Platelets / cytology
  • Blood Platelets / drug effects*
  • Blood Platelets / microbiology
  • Blood Platelets / radiation effects*
  • Furocoumarins / pharmacology*
  • Humans
  • Platelet Transfusion / methods*
  • Platelet Transfusion / standards
  • Riboflavin / pharmacology
  • Ultraviolet Rays

Substances

  • Furocoumarins
  • amotosalen
  • Riboflavin